Suppressing effect of perilla oil on azoxymethane-induced foci of colonic aberrant crypts in rats.
We have investigated the modulatory effect of dietary perilla oil which is rich in the n-3 polyunsaturated fatty acid, alpha-linolenic acid, on the development of azoxymethane (AOM)-induced colonic aberrant crypt foci (ACF) in male F344 rats. Animals were given three weekly subcutaneous injections of AOM (15 mg/kg body weight) to induce ACE. The rats were fed a basal diet containing either 12% olive oil, 12% safflower oil, 12% perilla oil, 6% perilla oil plus 6% olive oil, or 3% perilla oil plus 9% olive oil for 5 weeks, starting 1 week before the first dosing of AOM. All rats were sacrificed 2 weeks after the last AOM injection. The amount of food consumed and body weight gain were identical among every dietary group. The frequency of ACF was significantly lower in the rats fed 12% perilla oil than in those fed 12% olive oil or 12% safflower oil (P < 0.01 and P < 0.05, respectively). The suppressive effect of perilla oil was dose-dependent, as the number of ACF was 20.7, 40.7 and 47.4% of those of the 12% olive oil-fed controls in rats fed 12% perilla oil, 6% perilla oil plus 6% olive oil and 3% perilla oil plus 9% olive oil, respectively. Perilla oil significantly reduced ras expression as well as the AgNORs count (cell proliferation biomarkers) in the colonic mucosa, as compared with olive oil or safflower oil (P < 0.01, respectively). Marked increases in n-3 polyunsaturated fatty acids in membrane phospholipid fractions and decreased PGE2 levels were observed in colonic mucosa of perilla oil-fed rats. These results suggest that perilla oil, even in small amounts, suppresses the development of aberrant crypt foci, and is therefore a possible preventive agent in the early stage of colon carcinogenesis.
Onogi
N
N
First Department of Internal Medicine, Gifu University School of Medicine, Japan.
Okuno
M
M
Komaki
C
C
Moriwaki
H
H
Kawamori
T
T
Tanaka
T
T
Mori
H
H
Muto
Y
Y
D000818:Animals; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D001397:Azoxymethane; D001835:Body Weight / Q000187:drug effects; D002273:Carcinogens; D002455:Cell Division / Q000187:drug effects; D003106:Colon / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D003110:Colonic Neoplasms / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*; D015237:Dinoprost / Q000096:biosynthesis; D004305:Dose-Response Relationship, Drug; D004435:Eating / Q000187:drug effects; D015525:Fatty Acids, Omega-3 / Q000378:metabolism; D007413:Intestinal Mucosa / Q000187:drug effects / Q000378:metabolism; D008297:Male; D009697:Nucleolus Organizer Region / Q000187:drug effects; D010743:Phospholipids / Q000378:metabolism; D010938:Plant Oils; D011230:Precancerous Conditions / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*; D051381:Rats; D011916:Rats, Inbred F344; D016622:Silver Staining; D017962:alpha-Linolenic Acid / Q000633:toxicity*
D016588:Anticarcinogenic Agents; D002273:Carcinogens; D015525:Fatty Acids, Omega-3; D010743:Phospholipids; D010938:Plant Oils; D017962:alpha-Linolenic Acid; C058216:perilla seed oil; D015237:Dinoprost; D001397:Azoxymethane